[go: up one dir, main page]

WO1998042348A1 - Composition hydratante topique et methode associee - Google Patents

Composition hydratante topique et methode associee Download PDF

Info

Publication number
WO1998042348A1
WO1998042348A1 PCT/US1997/004985 US9704985W WO9842348A1 WO 1998042348 A1 WO1998042348 A1 WO 1998042348A1 US 9704985 W US9704985 W US 9704985W WO 9842348 A1 WO9842348 A1 WO 9842348A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
composition
lecithin
acid
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/004985
Other languages
English (en)
Inventor
Wilson Trafton Crandall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU25503/97A priority Critical patent/AU2550397A/en
Priority to PCT/US1997/004985 priority patent/WO1998042348A1/fr
Publication of WO1998042348A1 publication Critical patent/WO1998042348A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/90—Block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair

Definitions

  • the present invention is related to a process and composition for moisturizing and rejuvenating keratinous tissues including skin, hair, fingernails, and toenails of humans and animals, and also hooves and horns of animals. More particularly, the present invention relates to topically applying the composition disclosed herein in order to treat the affected keratinous tissue.
  • the skin is the largest organ in the body and serves several important functions that are essential to life.
  • the skin retards dehydration and also acts as a barrier to the invasion of various pathogens and noxious substances.
  • Skin is composed of the epidermis, or upper layer, and the subjacent derrnis.
  • the epidermis is the superficial layer and gives rise to the nails, hair, sebaceous glands, sweat glands, and the parenchyma of mammary glands.
  • the epidermis is composed of several layers. As cells from the deeper layer, the stratum germinativum, move toward the surface, they begin to synthesize the intracellular protein keratin.
  • stratum corneum which is comprised of several layers of cornified epidermal cells that are embedded in an intercellular matrix of semi-polar and polar lipids.
  • This layer acts as a transport route for various drugs, such as hydrocortisone, and also acts as a barrier to the transport of other drugs and cosmetics (Elias et al., Journal of Investigative Dermatology 73:
  • this hpid layer of the stratum corneum assists in the retention of water.
  • the water content of the stratum corneum has a profound influence on the appearance, flexibility, texture, and dryness of the skin, and also on the absorption of drugs and other molecules into and through the skin.
  • the skin gradually loses ceramides and water and becomes drier, less flexible and supple, more wrinkled, and scaly in appearance.
  • One of the major objectives of the cosmetic industry is to retard the drying and wrinkling of the skin that occurs with normal aging or as the result of exposure to wind, sun, cold and chemicals. As the mean age of the population increases, more people are seeking products that will retard the effects of aging on the skin and will essentially rejuvenate the skin. Increasing the moisture content of the skin is one mechanism for achieving this objective.
  • enhanced skin hydration facilitates the transport of pharmaceuticals across the epidermis to reach the underlying dermis and subjacent capillaries of the lymphatic and circulatory systems.
  • Another objective of the cosmetic industry is to retard the drying of the hair, fingernails and toenails, which all arise from the epidermis.
  • increased hydration of these structures prevents the painful effects of cracked nails and itchy, scaly scalp.
  • similar problems can occur with fingernails and toenails and also with horns and hooves which are all epidermal derivatives.
  • cracked hooves can result in lameness or in injury to the coronary band, the primary growth and nutritional source for the hoof wall. Injuries to the coronary band can cause serious permanent defects in the growth of the hoof wall.
  • Catz et al. in U.S. Patent No. 5,238,933, discloses skin permeation enhancer systems which increase the permeability of the skin to transdermally administered, pharmacologically active agents.
  • compositions for enhancing the penetration of pharmacologically active agents such compositions comprising a sugar ester in combination with a sulfoxide or phosphine oxide.
  • Loucks in U.S. Patent No. 4,701 ,471 , discloses a cosmetic and pharmaceutical composition comprising bovine bone marrow acids mixed with lecithin for prevention of the fatty acid oxidation and odor putrefacation.
  • Oleniacz discloses moisturizing units for treating keratinous tissue comprising liposomes having a ternary hpid mixture of lecithin, dicetyl phosphate, and a sterol.
  • Sakai et al. in U.S. Patent No. 4,760,096, discloses a skin moisturizing method and preparation containing a combination of a phosphatide such as soy lecithin, and one or more C 10 -C 30 carboxylic acid sterol esters.
  • U.S. Patent No. 4,783,450 to Fawzi et al. discloses the use of lecithin as a skin penetration enhancer for transdermal delivery of the drug procaterol through skin.
  • a method and composition for increasing the moisture of epidermal structures are needed.
  • the composition should be easy to apply topically, enhance moisture retention, and also have the capacity to deliver compounds that will assist in moisturizing and rejuvenating keratinous structures such as the skin hair, fingernails, toenails, hooves and horns.
  • the present invention provides an easy to use therapeutic and cosmetic process for treating dry skin and for alleviating the associated irritation and cracking of the skin by topically applying the composition disclosed herein.
  • Use of this process and composition increases the moisture content of the skin, reduces wrinkling, and provides a rejuvenated appearance to the skin.
  • this invention has great utility for the treatment of dry and brittle fingernails and toenails, and the adjacent skin that often is dry and cracked.
  • this invention is a therapeutic and cosmetic process for apphcation to animals with cracked and damaged horns and/or hooves. A horn or hoof dressing in show horses and cattle would produce a more vibrant and healthy appearance.
  • rapid closure of cracks in hooves would prevent invasion by foreign material and reduce the incidence of infection.
  • An additional embodiment of the invention is a therapeutic and cosmetic process for the treatment of dry and thinning hair to provide increased hair growth and thickness. It is understood that the present invention also encompasses a method and composition for delivery of molecules including, but not hrnited, to elastin, collagen and collagen fragments, glucosamine, glucosamine sulfate, glycerol, urea, ceramides, dimethicone, N-decylmethyl sulfoxide, salicylic acid, lanolin, chondroitin sulfate, hyaluronic acid, squalene, and various alpha hydroxy compounds such as lactic acid, citric acid, and glycolic acid, into the epidermis, dermis and other keratinous tissue.
  • the present invention can include other pharmaceutically acceptable components such as gelling agents, compounding agents, scents and the hke.
  • the composition of the present invention can also include other pharmaceutically active agents such as antibacterial, antifungal. antipro
  • This invention addresses the need for an easy-to-use topical treatment for cosmetic and therapeutic purposes of keratinous structures including the skin, nails, and hair of humans and animals, and also for the treatment of the nails, hair, hooves, and horns of animals.
  • Still another object of the invention is to provide a composition and method for treating skin to rejuvenate the skin and decrease the aged appearance of the skin.
  • Another object of the invention is to provide a composition and method for treating psoriasis.
  • Yet object of the invention is to provide a composition and method for treating eczema.
  • Still another object of the invention is to provide a composition and method for treating windburn, chapped lips, sunburn, and skin dehyrated due to exposure to chemicals.
  • Yet another object of the invention is to provide a composition and method for treating the cracked teats of animals and humans to prevent mastitis.
  • Another object of the invention is to provide a composition and method for treating dry and thinning hair of humans and animals. Still another object of the invention is to provide a composition and method for treating calluses, corns, and any other skin conditions involving drying of the skin.
  • lecithin is used to mean a phosphatide called phosphatidylchohne and can be isolated from soybean, eggs and other sources including, but not hrnited to, heart, brain, and liver.
  • Lecithin is a mixture of the diglycerides of steric, palmitic, and oleic acids, linked to the choline ester of phosphoric acid.
  • Soybean lecithin is a preferred lecithin and may contain the following acids; palmitic, stearic, palmitoleic, oleic, linoleic, linolenic and arachidonic as described in the Merck Index (Ninth edition, 1976, page 711).
  • PLURONIC refers to poloxamer compounds and are sold collectively under the trademark PLURONIC (BASF, Parsippany, NJ).
  • PLURONIC F-127 corresponds to poloxamer 407, a polyoxypropylene-polyoxyethylene block copolymer described by Schmolka in the Journal of Biomedical Materials Research 6:
  • moistureturize or derivatives thereof, relates to the conservation or enhancement of the water content of the keratinous tissue of animals and humans, with particular reference to the skin, hair, nails, hooves and horns.
  • Topical apphcation is used to mean local administration of the composition and its various embodiments, for example, in the treatment of dry skin.
  • pharmaceutically active agent relates to any chemical material or compound suitable for topical administration which includes any desired local effect on animal or human tissue contacted therewith and is sometimes referred to as a "penetrant".
  • pharmaceutically effective carrier is used herein to mean any liquid, gel, salve, solvent, liquid, diluent, fluid ointment base, and the like, which is suitable for use in contact with living animal or human tissue without causing adverse physiological responses, and which does not interact with the other components of the composition in a deleterious manner.
  • terapéuticaally effective amount of a molecule, drug or pharmacologically active agent is meant a nontoxic but sufficient amount to provide the desired therapeutic effect.
  • PLURONIC BASF, Parsippany, NJ
  • N-decylmethyl sulfoxide can be observed in many ways known to those skilled in the art.
  • keratinous tissue means skin, fingernails, toenails, hooves, horns and hair, and any other cells containing keratin.
  • the present invention provides a method and composition for topically treating damaged or diseased keratinous tissue resulting from any number of causes including, but not limited to: aging; chemical drying; radiation; burns from wind, sun, fire, cold, frostbite, radiation or chemicals; and dehydration resulting from skin disease, abrasion, sun, chemicals, wind, cold, fire, renal disease, colonic disease, hemorrhage, vasopressin imbalances, hypothalamic dysfunction, neurohypophyseal dysfunction, or other endocrine abnormalities.
  • the present invention includes a composition for topical treatment of keratinous tissue comprising the following components; lecithin, isopropyl palmitate and water.
  • lecithin organogel The combination of lecithin, isopropyl palmitate, and water is called lecithin organogel.
  • the present invention optionally includes lecithin organogel in combination with an approximately 20% solution of PLURONIC F-127 (BASF, Parsippany, NJ), otherwise known as poloxamer 407, in a ratio of approximately 1 : 4.
  • PLURONIC F-127 BASF, Parsippany, NJ
  • Other PLURONICS may be used in the present invention.
  • soy lecithin of the present invention is a preferred lecithin source and may be dissolved in isopropyl palmitate to achieve a final concentration in the composition of from approximately 20% - 90%, with a more preferred final concentration of from approximately 20% - 40%.
  • Lecithins may optionally be derived from eggs, and organs such as heart, brain and liver, and used at concentrations of approximately 20% - 99%, with more preferred final concentrations of from approximately 20% - 40%.
  • the composition according to the present invention can be in the form of lotions, salves, creams, ointments, liposomes, sprays, or gels.
  • the desired form is lotions, ointments and salves. Liposomes are described in detail by Oleniacz in U.S. Patent No. 3,957,971 , the entirety of which is hereby incorporated by reference.
  • the method and composition of the present invention cause an increase the water content of the skin, perhaps by increasing the fluid content of the epidermis and derrnis. It is believed that the composition of the invention enhances diffusion of moisturizers, surfactants, and emollients into and possibly through the epidermal and dermal layers of the skin. It is understood that the present invention also encompasses a method and composition for delivery of molecules into the skin.
  • These molecules optionally include, but are not hrnited to, elastin, collagen and collagen fragments, glucosamine, glucosamine sulfate, glycerol, urea, ceramides, dimethicone, N-decylmethyl sulfoxide, salicylic acid, lanolin, chondroitin sulfate, hyaluronic acid, squalene, and various alpha hydroxy compounds such as lactic acid, citric acid, and glycolic acid.
  • N-decylmethyl sulfoxide is included in the composition in a final concentration range of from 0.01 % to 1 % with a preferred range of 0.1 % to 0.5%.
  • the present invention increases the water content of the skin and decreases the wrinkled appearance.
  • Glucosamine or glucosamine derivatives such as glucosamine sulfate, that stimulate components of the extracellular matrix, can also be added to the present invention to plump up the appearance of the granular and basal cell layers.
  • a gelling agent optionally may be added to the formulation.
  • Gelling agents that are suitable for use in the present invention include, but are not hrnited to, cellulose ethers, alginates, polyacrylates, bentonite, gelatin, tragacanth, polyvinylpyrrolidone, polyvinyl alcohol, and polyoxyethylene/polyoxypropylene block copolymers, some of which are known as poloxamers.
  • the poloxamer compounds are sold collectively under the trademark PLURONIC (BASF, Parsippany, NJ).
  • PLURONIC F-127 corresponds to poloxamer 407.
  • Other PLURONICS may be used in the present invention.
  • a preservative such as sorbic acid, can be added to the composition. Other preservatives well known to those of ordinary skill in the art can be used in the composition.
  • a desired aroma improving agent is honey almond oil (PCAA, Kinghurst,
  • aroma improving agents include, but are not hrnited to, avocado oil, sesame oil, castor oil, olive oil, grapeseed oil, clove oil, groundnut oil, corn oil, lemon oil, coconut oil, lime oil, hazelnut oil, jojoba oil, carthamus oil and wheatgerm oil.
  • the oils can be added individually or in combination. It is to be understood that various fragrances and assorted floral scents may be optionally added to the composition and are commercially available (PCAA, Houston, TX).
  • Stabilizers, antioxidants, preservatives, humectants, regreasing agents, solvents or auxiliaries can be added to improve stability and/or adhesiveness of the formulations.
  • antimicrobial agents can be optionally added to the composition of the present invention if required. Addition of an antimicrobial agent is desirable when treating inflammatory conditions associated with acne, psoriasis or eczema.
  • the composition of the present invention can be administered topically either once daily or several times per day depending upon the nature and severity of the condition being treated.
  • Lecithin Organogel Composition Prepared With Pluronic A preferred composition was prepared as described below.
  • the lecithin organogel was prepared by dissolving 20 g of soy lecithin granules (PCAA, Houston, TX) in 20 ml of isopropyl palmitate (PCAA, Houston, TX). The mixture was stirred periodically for 24 hours until the soy lecithin granules were dissolved.
  • the PLURONIC gel 20% stock solution was prepared by dissolving 16 g of PLURONIC F127 powder (BASF, Parsippany, NJ), also called poloxamer 407, in 80 ml of purified water. Potassium sorbate (160 mg; PCAA, Houston, TX) was added to the PLURONIC gel 20% stock solution as a preservative. This was placed in the refrigerator at about 4°C for about 24 hours and stirred periodically.
  • the composition was prepared by mixing 20 ml of the lecithin organogel with 2 ml of the honey almond oil (PCAA, Houston, TX) until a smooth mixture was prepared. Honey almond oil was added for fragrance. Next, 80 ml of the PLURONIC gel 20% stock solution was mixed in until a gel formed. A blender was used for this mixing step at room temperature with disinfected equipment. The gel was stored at room temperature.
  • Lecithin Organogel Composition Prepared Without Pluronic
  • the composition described in Example 1 was prepared using lecithin organogel without the addition of the PLURONIC gel 20% stock solution.
  • the final concentration of lecithin organogel was in the range of 20 - 40 % by modifying the ratio of lecithin organogel to water.
  • Example 3 Hand Treatment of Human Subjects The lecithin organogel composition (not including
  • composition to the Human Face
  • the composition was applied topically to this region 2 to 3 times per day. Within 10 days the wrinkled appearance of the skin was dramatically diminished. This skin appeared fuller and smoother. The wrinkling of the skin was greatly reduced with fine lines generally less evident
  • lecithin organogel with PLURONIC lecithin organogel with N-decylmethyl sulfoxide and alpha hydroxyacids (glycolic or lactic acids partially neutrahzed with sodium hydroxide), urea and salicylic acid.
  • the results showed a qualitative increase in the hair shaft diameter.
  • regrowth of the hair was faster after treatment with lecithin organogel containing PLURONIC
  • alpha hydroxy compounds which have a low pH (about 1.2), adjust the pH to a value of about 5-5.5 with a base such as sodium hydroxide, and apply a 20-25% concentration to the hair overnight.
  • the hair would be washed the next morning, thereby enhancing absorption of water into the hair.
  • the result would be thicker and more luxurious hair.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne des méthodes et des compositions permettant de traiter localement les structures kératiniques des êtres humains et des animaux, notamment la peau, les cheveux ou poils, les ongles des mains et des pieds, les sabots et les cornes.
PCT/US1997/004985 1997-03-25 1997-03-25 Composition hydratante topique et methode associee Ceased WO1998042348A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU25503/97A AU2550397A (en) 1997-03-25 1997-03-25 Topical moisturizing composition and method
PCT/US1997/004985 WO1998042348A1 (fr) 1997-03-25 1997-03-25 Composition hydratante topique et methode associee

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1997/004985 WO1998042348A1 (fr) 1997-03-25 1997-03-25 Composition hydratante topique et methode associee

Publications (1)

Publication Number Publication Date
WO1998042348A1 true WO1998042348A1 (fr) 1998-10-01

Family

ID=22260602

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/004985 Ceased WO1998042348A1 (fr) 1997-03-25 1997-03-25 Composition hydratante topique et methode associee

Country Status (2)

Country Link
AU (1) AU2550397A (fr)
WO (1) WO1998042348A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10020937A1 (de) * 2000-04-28 2001-11-08 Mfh Marienfelde Gmbh Unternehm Zubereitung zur Hufpflege
WO2001083031A3 (fr) * 2000-05-01 2002-04-11 Bioderm Inc Composition topique pour le traitement du psoriasis et d'affections cutanees associees au psoriasis
WO2002078649A3 (fr) * 2001-03-30 2002-12-12 Oreal Compositions comprenant au moins un compose de type saccharide et leur utilisation pour proteger et/ou reparer les cheveux
WO2005002591A1 (fr) * 2003-07-02 2005-01-13 Fouad Abdelaziz Ahmed Hassanin Traitement du psoriasis, de l'impetigo, de la teigne par lipositol, cephaline et lecithine
FR2884423A1 (fr) * 2005-04-18 2006-10-20 Dicophar Soc Civ Ile Utilisation de la lecithine comme medicament dans le traitement du psoriasis
WO2006111633A3 (fr) * 2005-04-18 2007-04-05 Sc Dicophar Utilisation de la lecithine comme medicament dans le traitement du psoriasis
GB2477534A (en) * 2010-02-05 2011-08-10 Ajit Lalvani Composition for the stimulation and regulation of the hair follicle

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957971A (en) * 1974-07-29 1976-05-18 Lever Brothers Company Moisturizing units and moisturizing compositions containing the same
US4760096A (en) * 1985-09-27 1988-07-26 Schering Corporation Moisturizing skin preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957971A (en) * 1974-07-29 1976-05-18 Lever Brothers Company Moisturizing units and moisturizing compositions containing the same
US4760096A (en) * 1985-09-27 1988-07-26 Schering Corporation Moisturizing skin preparation

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10020937A1 (de) * 2000-04-28 2001-11-08 Mfh Marienfelde Gmbh Unternehm Zubereitung zur Hufpflege
WO2001083031A3 (fr) * 2000-05-01 2002-04-11 Bioderm Inc Composition topique pour le traitement du psoriasis et d'affections cutanees associees au psoriasis
US7670620B2 (en) 2000-05-01 2010-03-02 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
CZ303216B6 (cs) * 2000-05-01 2012-05-30 Bioderm, Inc. Prípravek pro topickou aplikaci na kuži pri lécení psoriázy a príbuzných kožních onemocnení
WO2002078649A3 (fr) * 2001-03-30 2002-12-12 Oreal Compositions comprenant au moins un compose de type saccharide et leur utilisation pour proteger et/ou reparer les cheveux
WO2005002591A1 (fr) * 2003-07-02 2005-01-13 Fouad Abdelaziz Ahmed Hassanin Traitement du psoriasis, de l'impetigo, de la teigne par lipositol, cephaline et lecithine
FR2884423A1 (fr) * 2005-04-18 2006-10-20 Dicophar Soc Civ Ile Utilisation de la lecithine comme medicament dans le traitement du psoriasis
WO2006111633A3 (fr) * 2005-04-18 2007-04-05 Sc Dicophar Utilisation de la lecithine comme medicament dans le traitement du psoriasis
GB2477534A (en) * 2010-02-05 2011-08-10 Ajit Lalvani Composition for the stimulation and regulation of the hair follicle

Also Published As

Publication number Publication date
AU2550397A (en) 1998-10-20

Similar Documents

Publication Publication Date Title
US5639740A (en) Topical moisturizing composition and method
US5945409A (en) Topical moisturizing composition and method
US5326566A (en) Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
US7740875B2 (en) Organo-gel formulations for therapeutic applications
AU2005294216C1 (en) Organo-gel formulations for therapeutic applications
US6096326A (en) Skin care compositions and use
EP0954278B1 (fr) Compositions pharmaceutiques contenant de l'huile de noix de kukui
EP2244690B1 (fr) Compositions topiques utilisées pour traiter des maladies et affections inflammatoires
JPH08505630A (ja) ウマの初乳を含む医薬用および皮膚美容用の組成物
AU660017B2 (en) Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
KR930001805B1 (ko) 안정성이 개선된 트리티노인 유화크림 제제
KR100673044B1 (ko) 경피 투여용 국소 조성물
US20090197819A1 (en) Compositions for improving and repairing skin
US20110236503A1 (en) Topical Skincare Composition
WO2013050959A1 (fr) Composition pour le traitement de lésions de la peau
JP2005524651A (ja) にきびの治療のための局所用ダプソン
US7262224B2 (en) Cosmetic rejuvenating and healing product, method of its manufacture and uses thereof
WO1998042348A1 (fr) Composition hydratante topique et methode associee
US20060222689A1 (en) Skin care compositions and methods
JPH0778026B2 (ja) 皮膚用外用基剤
WO2019175902A1 (fr) Préparation topique pour diverses affections cutanées
RU2325900C2 (ru) Состав для кожи наружного применения
WO1997018804A1 (fr) Rajeunissement de la peau a l'aide d'une combinaison de vitamine a et d'acides alphahydroxy
JP2023509971A (ja) 毛髪成長の刺激
KR20070006626A (ko) 피부의 국부조성물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: CA

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998545632

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase